NCT00663195CompletedPhase 4
Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Tottori University Hospital
- Enrollment
- 16
- Primary Endpoint
- MMP levels
Study Overview
Brief Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Detailed Description
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •chronic stable heart failure
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
MMP levels
Time Frame: 16 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Unknown
Phase 3
Spironolactone on Acute Kidney Injury in Critically Ill PatientsAcute Kidney InjuryNCT03206658Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran90
Completed
Phase 2
The effect of spironolactone in treatment of heart failureHeart Failure.Congestive heart failureIRCT2015101924597N1Vice chancellor for research of Iran university of medical sciences60
Completed
Phase 4
Evaluation of effect of spironolactone on proteinuria in kidney transplant patientsIRCT20230516058205N1Esfahan University of Medical Sciences60
Unknown
Phase 4
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial HypertensionPulmonary HypertensionNCT01468571Baylor College of Medicine50
Completed
Phase 1
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney DiseaseHeart FailureNCT01598740Sorbent Therapeutics18